Skip to main content
Equibles
AZR logo

AZR · Azora Therapeutics, Inc. (DE) · Metrics

Track AZR — free

Use AZR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AZR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.00 +0.29 (+7.82%) At close · Nov 6
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“the Company has concluded that there is substantial doubt about its ability to continue as a going concern.”
View the 10-Q filed Aug 14, 2026
Market Cap
$10.50M
Shares
2.63M
Volume · Nov 6 78.19K Avg daily vol (3M) 52.9K

AZR metrics

48 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$4.00
Market cap
$10.50M

Price action

23 metrics
Price change (1W)
-24.0%
Price change (30D)
-7.0%
Price change (3M)
-22.7%
Price change (6M)
+161.3%
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
119.5%
Annualized volatility (3M)
145.9%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
0.9
RSI (14D)
45.4
Price vs SMA 50
-18.2%
Price vs SMA 200
—
Avg volume (3M)
54,443
Relative volume
0.3
Average dollar volume
$261,075

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
2.63M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-593.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2022-11-15

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$57.68M
Net income (TTM)
−$57.80M
Trailing 12 months
Diluted EPS (TTM)
$-11.53
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
$-409.91
Capital expenditures per diluted share (TTM)
$2.41
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$4.75

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+987.7%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-198.7%
Debt / equity
—
Current ratio
5.6
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
5.6
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$28.71M
Latest balance sheet
Cash & equivalents
$28.71M
Total assets
$29.09M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$11.13M
Capital expenditures (TTM)
$64,605
R&D (TTM)
$2.01M
SG&A (TTM)
—
Stock compensation (TTM)
$600,200
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
17
13F filer change QoQ
+2
Institutional ownership
5.2%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
3.0%
Private-fund adviser ownership
1.5%
Active holders' share change QoQ
+2,713.9%
Holder tenure
3.7
Price vs estimated holder cost
-63.7%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.9%

Short interest

3 metrics
Short interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1513525 13F (30d) 10 filings 7 filers Visit website Investor relations